Ranbaxy Roundup: Problems Keep Coming For Beleaguered Firm
This article was originally published in PharmAsia News
Executive Summary
PharmAsiaNews gathered news reports chronicling a slew of problems, including a new Supreme Court of India order, still cropping up for Ranbaxy Laboratories even as it seeks to reassure its shareholders it is doing its best to resolve them.
You may also be interested in...
China Preps For First COVID Vaccine Roll-Outs
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
QUOTED. 3 December. Jessica Schubel.
A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.
Bukwang Speeds Lead Asset As It Eyes Danish Operation's Listing
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.
Need a specific report? 1000+ reports available
Buy Reports